Faculty & Staff Details

	Name:	Carlos Alvarez, Pharm.D., M.Sc., BCPS
	Position:	Assistant Professor, Clinical Research and Science Division, Dallas SW
	Email:	carlos.alvarez@ttuhsc.edu
	Bio	Dr. Alvarez is an Assistant Professor of Pharmacy Practice at Texas Tech University Health Sciences Center School of Pharmacy and an Advanced Practice Clinical Pharmacist in Primary Care at the VA Medical Center in Dallas. He received his Doctor of Pharmacy from Texas Tech University Health Sciences Center School of Pharmacy in 2004 and Master of Science in Advanced Pharmacotherapeutics and Research from The University of Texas at Austin in 2006. In conjunction with his M.S. degree, Dr. Alvarez completed a two-year Pharmacotherapy residency at The University of Texas Health Science Center in San Antonio. Dr. Alvarez is responsible for didactic clerkship teaching of Pharm.D. students and supervises their activities at the VA hospital Primary Care Clinics in Dallas.

Education:

Dr. Alvarez received his Doctor of Pharmacy from Texas Tech University Health Sciences Center School of Pharmacy in 2004.

Dr. Alvarez received his Master of Science in Advanced Pharmacotherapeutics and Research from The University of Texas at Austin College of Pharmacy in 2006.

In conjunction with his M.S. degree, Dr. Alvarez completed a two-year Pharmacotherapy residency at The University of Texas Health Science Center in San Antonio.

Licensures

July 2004 Registered Pharmacist
Texas License 42427
October 2007 Board Certified Pharmacotherapy Specialist

Awards

May 2008 – P2 Teaching Team of the Year Award (Endocrine Team)
November 2006 - Best Resident/Fellow Poster ACCP Annual Meeting

August 2006 - Summa Cum Laude (GPA 4.00)
Master of Science in Pharmacy, The University of Texas at Austin

May 2004 - Summa Cum Laude (GPA 3.93)
Doctor of Pharmacy Texas Tech University Health Sciences Center School of Pharmacy

May 2004 - Facts and Comparisons Excellence in Clinical Communications Award winner

Fall 2003 & Spring 2004 - Dean’s List, Texas Tech School of Pharmacy

2003 – 2004 - Bexar County Pharmacy Association Scholarship

2002-2003 - School of Pharmacy Academic Achievement Scholarship

Research Interests:

Dr. Alvarez’s areas of research interest are in the management of patients with the syndrome of insulin resistance, the prevention of diabetes, and the treatment of lipid disorders in the primary care setting.

Practice Focus:
Dr. Alvarez’s works in a multidisciplinary team to reduce complications associated with diabetes mellitus, hypertension, dyslipidemia and thyroid disorders at the VA medical center in Dallas.

Professional Service:
He is an active member of American College of Clinical Pharmacy, American Society of Health System Pharmacists, American Pharmaceutical Association, National Lipid Association, and the American Diabetes Association.

Publications:

Master’s Thesis
1. Alvarez CA, Wiederhold NP, Talbert RL, Burgess DS, Peters J, Williams RO III. Aerosolized Nanoparticles of Itraconazole for the Prevention of Invasive Pulmonary Aspergillosis Due to A. fumigatus in a Murine Model [thesis]. Austin, TX: The University of Texas at Austin, 2006.

Original Research Articles
1. Alvarez CA, Wiederhold NP, McConville JT, Peters JI, Najvar LK, Graybill JR, Marks D, Talbert RL, Burgess DS, Bocanegra R, Johnston KP, Williams RO III. Aerosolized nanostructured itraconazole as prophylaxis against invasive pulmonary aspergillosis. J Infect. 2007 Jul;55(1):68-74.

Reasearch Abstracts
1. Alvarez CA, Grabinski JL, Talbert RL, Wiederhold NP. Molecular Characterization of Aspergillus fumigatus isolates with elevated itraconazole, voriconazoe and posaconazole minimum inhibitory concentrations (abstract #124). Pharmacotherapy 2006; 26:e70
2. Alvarez CA, Wiederhold NP, McConville JT, Peters JI, Najvar LK, Graybill JR, Marks D, Talbert RL, Burgess DS, Bocanegra R, Johnston KP, Williams RO III. Aerosolized Nanostructured Itraconazole is effective as Prophylaxis against Invasive Pulmonary Aspergillosis due to Aspergillus fumigatus (abstract #125e). Pharmacotherapy 2006; 26:e70
3. Russell NM, Alvarez CA, Busti AJ, Chastain LM, Edwards KL, Greene RS, Weideman RA. Combination Thiazolidinedione (TZD) and Fibrate Effect on High Density Lipoprotein Concentration (HDL-C) (abstract #107). Journal of Clinical Lipidology 2008; 2(3):204.

Review Articles
1. Alvarez CA, Triplitt C. Combination Therapy for Hypertension and Dyslipidemia in Patients with Diabetes. Drug Benefit Trends. 2005; 17:11-20.
2. Alvarez CA. Inhaled Insulin Therapy for Patients with Diabetes Mellitus. Drug Benefit Trends 2008 Feb;20(2):63-70.

3. Edwards KE, Alvarez CA, Irons BK, Fields J. Third Line Agent Selection for Patients with Type 2 Diabetes Uncontrolled on Sulfonylurea and Metformin Therapy: A Review of the Literature. Pharmacotherapy. 2008 Apr;28(4):506-21.

Book Chapters
1. Alvarez CA, Triplitt C. Inhaled Insulin Therapy for Patients with Diabetes Mellitus. In: Advanced Drug Formulation Design to Optimize Therapeutic Outcomes. Eds. Williams III RO, Taft DR, McConville JT. Informa Healthcare Inc. New York, NY 2008. 113-142.
Editorials and Letters
1. Alvarez CA, Mascarenas C, Timmerman I. Increasing psychosis in a patient switched from clozaril to generic clozapine. Am J Psychiatry. 2006 Apr;163(4):746.

Invited Electronic Publications
1. Alvarez CA, Linn WD, Moore TD, O’Rourke RA. Hot Topic: Left Ventricular Hypertrophy- To Regress or Not Regress, That is Not the Question. Hurst’s The Heart 11th ed.
2. Alvarez CA, Linn WD, Moore TD, O’Rourke RA. Angiotensin Receptor Blockers in Heart Failure- A New Answer to an Old Question. Hurst’s The Heart 11th ed.

Invited Presentations
1. The Future of Inhaled Insulin. Invited presentation at the Texas Society of Health System Pharmacists annual meeting. April 21, 2007 San Antonio, TX
2. The Tumultuous Year in Diabetes Treatment. Invited presentation at the Texas Society of Health System Pharmacists annual meeting. April 2008 Dallas TX